Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 9, 2017

View Archived Issues

Kancera reports on ROR inhibitor KAN-0441571

Phase III NAVIGATE ESUS study of Xarelto stopped early for futility

Kadmon's KD-025 granted U.S. orphan drug status for cGVHD

Multiple-dosing study finds antibacterial KBP-7072 safe in healthy subjects

SYN-004 protects gut microbiome, reduces C. difficile infection in proof-of-concept study

APX-001 first-in-human results show promise

Shanghai Institute Materia Medica patents IDH1 inhibitors

Immune Sensor and collaborator divulge new hSTING agonists

Shenzhen Targetrx Biotechnology identifies HBV and HIV compounds

University of Michigan and Kura Oncology patent menin-MLL interaction inhibitors

Selexis to help advance Pelican Therapeutics' immunotherapy clinical candidates

Harmony Biosciences gains U.S. rights to pitolisant and completes equity financing

New endonucleases inhibitors presented by Biotech Innovations

Medibio to work with Otsuka to characterize sleep biomarkers related to mental illness

Emergent BioSolutions completes ACAM2000 acquisition

FDA grants new breakthrough therapy designation to Tagrisso in NSCLC

New phase I study explores BMS-986224 in healthy subjects and heart failure patients

EMA accepts Imfinzi MAA for locally advanced unresectable NSCLC

DS-2969b shows minimal disruption of normal gut flora in phase I study

Unum studies ACTR-707 with rituximab in subjects with relapsed or refractory B-cell lymphoma

Shionogi presents results on baloxavir marvoxil in combination with neuraminidase inhibitors

Australian grant supports Indo-Pacific efforts to combat tuberculosis and infectious disease

FDA announces grants for clinical trials and natural history studies

FDA approves Zilretta for osteoarthritis knee pain

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 2, 2026.
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
AND-017 increases RBC and hemoglobin in sickle cell disease
BioWorld Science
Sickle cell disease (SCD) is an inherited hemoglobinopathy caused by a mutation in the gene encoding β-globin that results in hemoglobin S polymerization, red...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...